IDXX vs IQV — Key Metrics
| Metric | IDXX (IDEXX LABORATORIES INC) | IQV (IQVIA HOLDINGS INC) |
|---|---|---|
| Price | 698.47 | 257.84 |
| Market Cap | 55.03 Billion | 42.49 Billion |
| P/E (TTM) | 46.81 | 31.03 |
| P/B (Quarterly) | 28.31 | 6.719 |
| P/S (TTM) | 11.8 | 2.45 |
| Net Profit Margin (TTM) | 25.4 | 8.1 |
| Gross Margin (TTM) | 62.7 | 33.1 |
| ROE (TTM) | 71.2 | 21.8 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Underperform
Underperform
Recommendation Summary
Stock IDXX is projected to greatly underperform the market, stock IQV is projected to underperform the market. Upfront Recommendation: IQV.
Financial Metrics
| IDXX | Metrics | IQV |
|---|---|---|
| $698.47 | Price | $257.84 |
| — | Market Capitalization | — |
| 46.81 | Price to Earnings Ratio | 31.03 |
| 11.8 | Price to Sales | 2.45 |
| 42.65 | Price to FCF Ratio | 20.44 |
| 18.82 | Price to Gross Profit | 7.42 |
| 36.69 | Price to Current Assets | 6.59 |
IDXX vs IQV at a glance
Idexx Laboratories INC (IDXX) and Iqvia Holdings INC (IQV) are both Diagnostics & Research companies in the Healthcare sector. IDXX is the larger, at $55.0 billion in market value against $42.5 billion for IQV, about 1.3 times the size.
On trailing-twelve-month figures, IDXX trades at 46.8 times trailing earnings and IQV at 31.0; net profit margins are 25.4% and 8.1%.
The Upfront Investment model currently rates IDXX Greatly Underperform and IQV Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.